HALIFAX, NS, Jan. 9 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, announced today that it will present at the OneMedPlace Finance Forum on Tuesday, January 13, 2009 in San Francisco, CA. For more information visit www.onemedplace.com.
Dr. Randal Chase, president and CEO of ImmunoVaccine Technologies Inc., will speak at 8:45 am PST on the development of its superior vaccine delivery system, DepoVax(TM). DepoVax(TM) is being used to develop a single-dose rapid response pandemic influenza vaccine and a potent immunotherapeutic vaccine. The DepoVax(TM) platform has broad applicability with any antigen, including DNA-based antigens, and can also be used for SiRNA therapies.
ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a private, clinical-stage, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.
In January 2008, IVT licensed its technology to Pfizer Animal health for two indications for infectious diseases in livestock, marking a pivotal step in achieving its vision of delivering breakthrough vaccines. www.immunovaccine.com.
|SOURCE ImmunoVaccine Technologies Inc.|
Copyright©2009 PR Newswire.
All rights reserved